- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02186418
Transferência de genes para pacientes com doença falciforme
Transferência de genes para pacientes com doença falciforme usando um vetor de lentivírus de gama globina: um estudo piloto de fase 1/2 de rótulo aberto
The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell collection and gamma-globin gene transfer, and success of gene correction in subjects with sickle cell disease
Visão geral do estudo
Descrição detalhada
This study will assess the feasibility, safety and efficacy of gene transfer using ARU-1801 (CD34+ cells transduced with the gamma-globin lentiviral vector). Gene transfer will occur ex-vivo into CD34+ enriched human bone marrow or plerixafor-mobilized peripheral blood hematopoietic stem cells (HSC) collected from subjects with severe sickle cell disease (SCD). Subjects will undergo reduced intensity chemotherapy conditioning with single-dose melphalan to facilitate engraftment of ex-vivo ARU-1801 via IV infusion. Subjects will return to the study site at regular intervals for follow-up for 2 years after the ARU-1801 infusion. It is anticipated that a separate long-term follow-up (LTFU) clinical study will be initiated, in which all subjects completing the 2 year study visit will be asked to consent and enroll, and will followed for a further 13 years.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria
-
Signed informed consent form.
-
Has confirmed diagnosis of sickle cell disease (SCD)
-
Has severe sickle cell disease, defined as one or more of the following:
- Minimum of two episodes of clinically diagnosed acute chest syndrome (ACS) requiring hospital admission, or one life threatening episode of ACS requiring intensive care unit (ICU) admission for exchange transfusion and/or intubation, or frequent ACS episodes which necessitate treatment with chronic transfusion therapy.
- Frequent painful vaso-occlusive episodes (VOEs) which significantly interfere with normal life activities, defined as a history of 2 or more severe acute sickle pain events per year requiring additional treatment at a medical facility outside of home pain management over the preceding 2-year period prior to study enrollment, or that necessitate chronic transfusion therapy.
- Subjects on chronic transfusion therapy for severe disease symptoms other than those listed above, and which interfere with normal life activities.
-
Has failed hydroxyurea therapy, was unable to tolerate hydroxyurea therapy, or has actively made the choice to not take the recommended daily hydroxyurea advised for severe disease (Note: must be off hydroxyurea therapy for 2 months prior to stem cell collection). If refusing hydroxyurea, the subject must document that they have been educated about the benefits and continue to refuse the treatment. Patients placed on chronic transfusion therapy instead of hydroxyurea for severe disease are eligible. Subjects unable to take hydroxyurea due to financial or safety monitoring constraints are eligible.
-
Has adequate functional status and organ function as determined at Screening.
Exclusion Criteria
- Female subjects who are pregnant or lactating/breastfeeding.
- Female subjects who are not surgically sterile, postmenopausal or who refuse to practice effective method of birth control as determined by the Investigator for one year after receiving the study drug. Women must also agree not to breastfeed for 1 year after receiving the study drug.
- Any participant of reproductive potential who refuses to agree to use an appropriate contraceptive method determined by the Investigator, for 1 year after receiving the study drug.
- Patients with an active malignant disease or receiving treatment for any type of cancer (except squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of the skin).
- Current diagnosis or history of hepatitis B, hepatitis C, or HIV.
- Has received another study drug within 30 days, or 5 half-lives of the last dose (whichever is longer), prior to screening.
- Has severe obstruction, restriction or diffusion defect on pulmonary function tests.
- Has uncontrolled bacterial, viral or fungal infections within 1 month prior to starting the conditioning part of the study. Subjects with fever should wait for symptoms to resolve before starting the conditioning part of the study.
- Has a history of stroke or is at moderate to high risk of primary stroke (eg receiving chronic transfusions or hydroxyurea for primary prevention of stroke; has severe cerebral vasculopathy defined as moderate stenosis in >2 arterial segments; and/or has sever stenosis/occlusion in ≤2 segments in the polygon of Willis or presence of Moyamoya-like disease).
- Patients with alpha thalassemia sickle cell disease.
- Has previous liver biopsy showing cirrhosis, bridging hepatic fibrosis, or active hepatitis; or has received chronic transfusions and has previous evidence of iron overload and evidence of liver fibrosis by noninvasive liver imaging.
- Has a matched sibling donor, unless the subject has declined this option or this option is not feasible. Documentation must be included as part of the informed consent process for subjects who decline this option.
- Has a known hypersensitivity to any study treatments (e.g. melphalan, plerixafor).
Other protocol-defined inclusion-exclusion criteria may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: ARU-1801
Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion. |
Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Grade 3 Allergic Reaction
Prazo: From infusion (Day 0) to 30 days post-infusion
|
Number of Participants with Grade 3 allergic reaction associated with infusion of transduced cell product |
From infusion (Day 0) to 30 days post-infusion
|
|
Number of Participants Grade 4 Infection
Prazo: From infusion (Day 0) to 30 days post-infusion
|
Number of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days |
From infusion (Day 0) to 30 days post-infusion
|
|
Total Number of Grade 4 Neutropenia
Prazo: From date of chemotherapy clearance visit to to 30 days post-infusion
|
Number of participants with Grade 4 neutropenia lasting >1 month following melphalan |
From date of chemotherapy clearance visit to to 30 days post-infusion
|
|
Number of Participants With Grade 3 or 4 Toxicity Events
Prazo: From infusion (Day 0) to 30 days post-infusion
|
Number of Participants with Grade 3 or 4 organ toxicity attributable to study procedures |
From infusion (Day 0) to 30 days post-infusion
|
|
Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE)
Prazo: From infusion (Day 0) to 30 days post-infusion
|
From infusion (Day 0) to 30 days post-infusion
|
|
|
Number of Death Due to Study Procedures
Prazo: From screening to the end of study, and up to 12 months.
|
From screening to the end of study, and up to 12 months.
|
|
|
Number of Hematological Malignancy
Prazo: From infusion (Day 0) to end of study, up to 12 months
|
Number of hematological malignancy due to vector insertion |
From infusion (Day 0) to end of study, up to 12 months
|
|
Number of Hematological Cancer
Prazo: From infusion (Day 0) to end of study, up to 12 months.
|
Number of hematological cancer related to investigational product or study medications/procedures |
From infusion (Day 0) to end of study, up to 12 months.
|
|
Time to Neutrophil Recovery
Prazo: From infusion (Day 0) to end of study, up to 12 months.
|
Duration of neutropenia following conditioning (defined as the time from first measurement where absolute neutrophil count (ANC) < 500 cells/µL to first of 3 consecutive absolute neutrophil count measurements on 3 consecutive days with ANC ≥500 cells/µL) |
From infusion (Day 0) to end of study, up to 12 months.
|
|
Time to Platelet Recovery
Prazo: From infusion (Day 0) to end of study, up to 12 months.
|
Duration of thrombocytopenia following conditioning (defined as the time from first measurement where platelet count < 50,000 cells/µL to the first of 3 consecutive platelet counts on 3 consecutive days > 50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days) |
From infusion (Day 0) to end of study, up to 12 months.
|
|
≥8x10⁶kg Viable CD34+ Cells
Prazo: Date of Enrollment to Infusion (day 0).
|
Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells |
Date of Enrollment to Infusion (day 0).
|
|
≥4x10⁶ CD34+ Cells/kg Body Weight Transduced
Prazo: Date of Enrollment to Infusion (day 0).
|
Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced |
Date of Enrollment to Infusion (day 0).
|
|
Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells
Prazo: Infusion (Day 0) to 1 year post infusion.
|
Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells |
Infusion (Day 0) to 1 year post infusion.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of HBF^G16D
Prazo: Infusion to 12 months post-infusion
|
Percentage of HBF^G16D relative to total Hemoglobin |
Infusion to 12 months post-infusion
|
|
Change in Proportion of Antisickling/Sickling Hemoglobin
Prazo: Enrollment to Month 24
|
Evaluation of the longitudinal change in the ratio of total antisickling hemoglobin fractions, comprising Fetal Hemoglobin (HbF), the gene-modified hemoglobin variant (HbFG16D), and Hemoglobin A2 (HbA2), relative to Sickling Hemoglobin (HbS). This outcome assesses the stable expression of the therapeutic transgene and the successful shift in the underlying hemoglobin profile post-infusion. Measurements will be performed using Capillary Zone Electrophoresis (CZE) to quantify the individual percentages of each hemoglobin fraction. The antisickling proportion is defined as the sum percentage: (HbF+HbFG16D+HbA2). This value will be compared between the baseline (pre-conditioning/pre-infusion) and the evaluable period through month 24 post-infusion to determine the sustained pancellular distribution of non-sickling hemoglobins. Higher values are considered a successful outcome. |
Enrollment to Month 24
|
|
Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)
Prazo: Infusion to 12 months post-infusion
|
This measure quantifies the proportion of newly formed red blood cells (reticulocytes) containing detectable levels of fetal hemoglobin (HbF). Because reticulocytes reflect the most recent erythropoietic activity (the last 24-48 hours), this percentage serves as a real-time indicator of the induction of HbF at the erythroid precursor level. This is measured by flow cyctometry. |
Infusion to 12 months post-infusion
|
|
Percent VCN at 6 Months
Prazo: Infusion to 6 months post-infusion
|
This measure assesses the percentage of infusion product Vector copy number (VCN) at six months post-infusion in each patient. VCN analysis is performed on DNA from the white blood cell fraction using quantitative polymerase chain reaction (qPCR). |
Infusion to 6 months post-infusion
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Stella M. Davies, MB BS, PhD, MRCP, Children's Hospital Medical Center, Cincinnati
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ARU-1801_Ph1_01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .